Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 10
Submit an article Journal homepage
7,533
Views
9
CrossRef citations to date
0
Altmetric
Editorial

Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice

Carla Francés ArtigasOxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK
, MD (Specialist Registrar in Diabetes and Endocrinology) ,
Victoria StokesOxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK
, MBBChir MRCP (Specialist Registrar in Diabetes and Endocrinology) ,
Garry D TanOxford Centre for Diabetes Endocrinology and Metabolism Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK
, MB DPhil FRCP (Consultant Physician in Diabetes and Clinical Director) &
Michael J TheodorakisUniversity of Oxford Diabetes Trials Unit, Oxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK+44 1865 857 230; +44 1865 857 241; [email protected]
, MD PhD FRCP (Senior Clinical Researcher and Honorary Consultant Physician)
Pages 1417-1421 | Published online: 16 Jun 2015

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Charles F. Shaefer & John Anderson. (2016) The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. Postgraduate Medicine 128:1, pages 137-144.
Read now

Articles from other publishers (8)

Zhen Feng, Wai Kei Tong, Xinyue Zhang & Zhijia Tang. (2023) Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Frontiers in Pharmacology 14.
Crossref
Kristin K. Clemens, Jaclyn Ernst, Tayyab Khan, Sonja Reichert, Mohammad Qasim Khan, Heather LaPier, Michael Chiu, Saverio Stranges, Gurleen Sahi, Fabio Castrillon-Ramirez & Louise Moist. (2023) Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review. Nutrition, Metabolism and Cardiovascular Diseases 33:6, pages 1111-1120.
Crossref
Ivona Risovic, Mirjana Sumarac Dumanovic, Mirjana Bojic & Danijel Djekic. (2023) Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes. BMC Endocrine Disorders 23:1.
Crossref
Kimberly Sassenrath, Beth Bryles Phillips & Rebecca H. Stone. (2021) Evaluation of GLP-1 Receptor Agonists in Combination With Multiple Daily Insulin Injections for Type 2 Diabetes. Journal of Pharmacy Practice 35:6, pages 979-990.
Crossref
Elizabeth Van Dril, Margaret Allison & Christie Schumacher. (2022) Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American Heart Journal Plus: Cardiology Research and Practice 17, pages 100163.
Crossref
José L. Górriz, Irene Romera, Amelia Cobo, Phillipe D. O’Brien & Juan F. Merino-Torres. (2022) Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. Diabetes Therapy 13:3, pages 389-421.
Crossref
Mohini Aras, Beverly G. Tchang & Joy Pape. (2021) Obesity and Diabetes. Nursing Clinics of North America 56:4, pages 527-541.
Crossref
Marie L. Davies, David Q. Pham & Scott R. Drab. (2016) GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:8, pages 893-905.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.